Liu Yang, Tang Qing, Shao Siying, Chen Yi, Chen Weihai, Xu Xiaoyu
College of Pharmaceutical Sciences and Chinese Medicine, Southwest University, Chongqing 400715, China; Institute of Chinese Medicine, Southwest University, Chongqing 400715, China; Chongqing Engineering Research Centre for Pharmacological Evaluation, Chongqing 400715, China.
Faculty of Psychology, Southwest University, Chongqing, 400715, China.
Int J Biol Sci. 2017 Feb 25;13(3):327-338. doi: 10.7150/ijbs.17751. eCollection 2017.
Catalpol and puerarin are two monomers of and , which are two herbs commonly used together in ancient prescriptions of traditional Chinese medicine for cerebral ischemia. Our previous study shows that the lyophilized powder of the two monomers improved the outcome of cerebral ischemia excellently in rodents. However, if it protects vessels from ischemia is unknown. The present research studied the protection of lyophilized powder of catalpol and puerarin (CP) on endothelial cells and the relative mechanism and . Middle cerebral artery occlusion (MCAO) rats were used to study the improvement of CP on neurological deficiency, regional cerebral blood flow (rCBF), and infarct volume. The morphology of vessels and the apoptosis of brain vascular endothelial cells (BVECs) were observed and detected by immunohistochemistry approaches. To study how CP protected primary BVECs (pBVECs) from ischemic penumbra, oxygen glucose deprivation (OGD)-damaged pBVECs were cultured in the condition of insufficient nutrition and low oxygen which recapitulate the low perfusion of ischemic penumbra. Using the cell model, the mechanism by which CP protected pBVECs was studied by shRNA and pathway inhibitors. CP at the dose of 65.4 mg/kg increased regional cerebral blood flow (rCBF), reduced infarct volume, protected vessel integrity and inhibited endothelial cell apoptosis . But it only improved rCBF, vessel integrity and BVECs apoptosis at the dose of 32.7 mg/kg. , the protection of CP on pBVECs was proved to be ERK/HIF-1a- and PI3K/AKT/mTOR/HIF-1a-dependent. This study indicates a possibility of CP being a new drug for cerebral ischemia. Besides, this research provides an alternative cell model for penumbra ECs study.
梓醇和葛根素是两种单体,它们是中药古代治疗脑缺血的常用配伍药材。我们之前的研究表明,这两种单体的冻干粉在啮齿动物中能显著改善脑缺血的预后。然而,其是否能保护血管免受缺血损伤尚不清楚。本研究探讨了梓醇和葛根素冻干粉(CP)对内皮细胞的保护作用及其相关机制。采用大脑中动脉闭塞(MCAO)大鼠模型,研究CP对神经功能缺损、局部脑血流量(rCBF)和梗死体积的改善作用。通过免疫组织化学方法观察和检测血管形态及脑血管内皮细胞(BVECs)的凋亡情况。为研究CP如何保护缺血半暗带的原代BVECs(pBVECs),在营养不足和低氧条件下培养氧糖剥夺(OGD)损伤的pBVECs以模拟缺血半暗带的低灌注情况。利用该细胞模型,通过shRNA和信号通路抑制剂研究CP保护pBVECs的机制。65.4mg/kg剂量的CP可增加局部脑血流量(rCBF),减少梗死体积,保护血管完整性并抑制内皮细胞凋亡。但32.7mg/kg剂量时仅改善了rCBF、血管完整性和BVECs凋亡。结果表明,CP对pBVECs的保护作用是ERK/HIF-1α和PI3K/AKT/mTOR/HIF-1α依赖性的。本研究表明CP有可能成为治疗脑缺血的新药。此外,本研究为半暗带内皮细胞研究提供了一种替代细胞模型。